Australia markets closed

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.6100+0.0100 (+0.28%)
At close: 04:00PM EDT
3.5200 -0.09 (-2.49%)
After hours: 04:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.6000
Open3.6100
Bid0.0000 x 800
Ask0.0000 x 1800
Day's range3.5300 - 3.7400
52-week range2.0700 - 23.3700
Volume305,047
Avg. volume650,217
Market cap209.272M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.8500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.50
  • Business Wire

    Graphite Bio Announces Participation in Jefferies Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., June 01, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.

  • Business Wire

    Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting

    SOUTH SAN FRANCISCO, Calif., May 16, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical data for GPH102, the company’s differentiated gene replacement program for beta-thalassemia, in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The hyb

  • Business Wire

    Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 12, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and first quarter 2022 financial results.